Latest Ratios: P/E Ratio -0.0x · EV/EBITDA N/A · ROE N/A. (1996–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $1M | $2M | $29M | $55M | $39M | $113M | $148M | $5M | $21M | $26M | $39M |
| Enterprise Value | $5M | $6M | $30M | $51M | $12M | $81M | $112M | $10M | $26M | $26M | $37M |
| P/E Ratio → | -0.04 | — | — | — | — | — | — | — | — | — | — |
| P/S Ratio | 12.07 | 20.78 | 170.97 | 274.53 | 274.05 | 836.75 | 906.99 | 36.45 | 56.21 | 59.57 | 424.36 |
| P/B Ratio | — | — | — | 5.42 | 1.00 | 1.99 | 2.41 | 0.40 | 3.99 | 2.99 | 2.52 |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 65.84 | 178.27 | 251.16 | 88.12 | 600.13 | 684.80 | 71.52 | 71.54 | 60.53 | 398.18 |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | -284.1% | -284.1% | 81.8% | 79.2% | 100.0% | -529.6% | -394.5% | -537.9% | -140.9% | -170.7% | -1104.3% |
| Operating Margin | -11961.4% | -11961.4% | -11630.6% | -15800.0% | -14129.7% | -13954.1% | -9295.7% | -8887.9% | -3132.4% | -2612.4% | -15004.3% |
| Net Profit Margin | -15861.4% | -15861.4% | -10188.2% | -14337.6% | -13790.8% | -14168.1% | -8834.4% | -6717.1% | -2673.8% | -1889.9% | -8154.3% |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | — | — | -388.7% | -118.9% | -40.8% | -32.4% | -38.8% | -104.0% | -141.4% | -68.3% | -41.8% |
| ROA | -194.0% | -194.0% | -123.8% | -96.8% | -39.6% | -22.7% | -21.9% | -55.2% | -70.0% | -49.9% | -36.0% |
| ROIC | — | — | -546.1% | -269.5% | -80.4% | -56.5% | -53.0% | -65.2% | -86.5% | -77.1% | -66.1% |
| ROCE | — | — | -403.4% | -128.0% | -41.4% | -22.6% | -23.5% | -90.0% | -114.7% | -81.7% | -75.0% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | — | — | — | 0.07 | 0.02 | 0.00 | 0.04 | 0.49 | 1.15 | 0.21 | — |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | — | — | -0.46 | -0.68 | -0.56 | -0.59 | 0.38 | 1.09 | 0.05 | -0.16 |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — | — | — | — |
| Interest Coverage | -12.96 | -12.96 | -28.61 | — | — | -284.48 | -20.43 | -21.02 | -18.58 | -58.42 | — |
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 0.53 | 0.53 | 0.44 | 1.68 | 26.69 | 74.61 | 36.58 | 9.27 | 0.72 | 1.29 | 2.85 |
| Quick Ratio | 0.53 | 0.53 | 0.44 | 1.72 | 26.69 | 74.61 | 36.58 | 9.27 | 0.72 | 1.29 | 2.85 |
| Cash Ratio | 0.16 | 0.16 | 0.42 | 1.51 | 25.12 | 71.72 | 35.39 | 7.79 | 0.34 | 0.78 | 2.41 |
| Asset Turnover | — | 0.02 | 0.02 | 0.01 | 0.00 | 0.00 | 0.00 | 0.01 | 0.03 | 0.03 | 0.00 |
| Inventory Turnover | — | — | — | — | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | 29.03 | — | 2139.41 | 4338.58 | 4436.78 | 2516.93 | 2137.86 | 1088.04 | 20.05 | — |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Shares Outstanding | — | $2M | $2M | $1M | $1M | $1M | $877903 | $100429 | $27689 | $17967 | $13669 |
Imminent liquidity exhaustion
According to recent market data, AIM trades at a P/S ratio of 12.07, a figure that appears largely disconnected from fundamental performance and instead reflects speculative pricing based on the binary potential of clinical trial outcomes rather than any underlying revenue-generating capability or sustainable business model.
The elevated P/S multiple is misleading because the company lacks a stable revenue base, rendering traditional valuation metrics ineffective for assessing intrinsic value. Investors should interpret this premium as a reflection of the market's willingness to assign value to the company's intellectual property and clinical pipeline, despite the absence of commercial success.
Based on reported financial statements, AIM's ROIC has consistently remained in deep negative territory, reaching -165.2% in 2024Q4, which indicates that the company is currently destroying rather than compounding invested capital as it funds long-term clinical development without a corresponding return on its research expenditures.
The persistent negative returns on capital highlight the structural inability of the current business model to generate value from its R&D investments. This trend suggests that the company's capital allocation strategy is primarily focused on survival through equity dilution rather than achieving a threshold of operational efficiency that would justify its cost of capital.
As reported in quarterly filings, the company's cash conversion cycle is effectively non-functional, with asset turnover near zero, illustrating that the firm's operational infrastructure is not currently optimized for commercial throughput or the efficient management of working capital in a traditional industrial sense.
The lack of meaningful asset turnover confirms that the company's manufacturing assets are underutilized and do not contribute to a self-sustaining revenue cycle. This inefficiency warrants further investigation into whether the company's Ocala facility can ever reach the scale required to achieve positive unit economics.
According to the company's balance sheet data, the debt-to-equity ratio of 2.15 in 2026Q1, combined with negative interest coverage, suggests that the firm's reliance on debt financing is becoming increasingly precarious as it lacks the operating cash flow necessary to service its existing financial obligations.
The negative interest coverage ratio indicates that the company is fundamentally unable to cover its interest expenses from operations, forcing a reliance on external capital markets. This leverage profile increases the risk of insolvency should the company fail to secure additional funding or if market conditions for biotech financing deteriorate further.
Based on an analysis of the company's business model, the P/S ratio is the most commonly misapplied metric, as it obscures the reality that AIM is a pre-commercial entity where revenue is incidental rather than a primary driver of value or a predictor of future profitability.
Analysts should instead focus on the 'Cash Runway to Milestone' ratio, which provides a more accurate assessment of the company's survival horizon. Relying on P/S multiples in this context risks misinterpreting a distressed, cash-burning entity as a growth-stage company, thereby ignoring the critical risk of imminent liquidity exhaustion.
Includes 30+ ratios · 30 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying AIM stock.
AIM ImmunoTech Inc.'s current P/E ratio is -0.0x. This places it at the 50th percentile of its historical range.
Based on historical data, AIM ImmunoTech Inc. is trading at a P/E of -0.0x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
AIM ImmunoTech Inc. has -284.1% gross margin and -11961.4% operating margin.